301258 Stock Overview
Engages in the manufacture and sale of biopharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Suzhou Fushilai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥23.89 |
| 52 Week High | CN¥43.39 |
| 52 Week Low | CN¥19.63 |
| Beta | 0.50 |
| 1 Month Change | 2.93% |
| 3 Month Change | -12.75% |
| 1 Year Change | 1.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.09% |
Recent News & Updates
Shareholder Returns
| 301258 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.5% | 0.009% | 0.02% |
| 1Y | 1.8% | 4.5% | 18.1% |
Return vs Industry: 301258 underperformed the CN Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: 301258 underperformed the CN Market which returned 18.1% over the past year.
Price Volatility
| 301258 volatility | |
|---|---|
| 301258 Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 301258 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301258's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 544 | Xiangyun Qian | www.fuslai.com |
Suzhou Fushilai Pharmaceutical Co., Ltd. engages in the manufacture and sale of biopharmaceutical products in China. It primarily focuses on manufacturing Alpha Lipoic Acid, L-Carnosine, and Phosphatidylcholine series of products. Its products are primarily used in medicines, dietary supplements, cosmetics, and other fields.
Suzhou Fushilai Pharmaceutical Co., Ltd. Fundamentals Summary
| 301258 fundamental statistics | |
|---|---|
| Market cap | CN¥2.18b |
| Earnings (TTM) | CN¥18.88m |
| Revenue (TTM) | CN¥413.15m |
115.4x
P/E Ratio5.3x
P/S RatioIs 301258 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301258 income statement (TTM) | |
|---|---|
| Revenue | CN¥413.15m |
| Cost of Revenue | CN¥325.13m |
| Gross Profit | CN¥88.02m |
| Other Expenses | CN¥69.15m |
| Earnings | CN¥18.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 22, 2025
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 21.31% |
| Net Profit Margin | 4.57% |
| Debt/Equity Ratio | 0% |
How did 301258 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield293%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 03:42 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Suzhou Fushilai Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.